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Objective:  To compare the safety and efficacy of tamsulosin, tadalafil, deflazacort and combination of
tamsulosin with tadalafil in lower ureteric orifice negotiation by large size ureteroscope (8/9.8 Fr) prior to
intracorporeal lithotripsy.
Patients  and  methods:  In this prospective study, 180 patients presented with ureteric stone of size 8–15 mm
were randomly assigned to 5 groups: tamsulosin (group A), tadalafil (group B), deflazacort (group C),
combination of tamsulosin with tadalafil (group D) and placebo (group E). After 10 days of drug therapy
168 patients were underwent ureteroscopy and findings like endoscopic configuration of ureteric orifice,
need for ureteric dilatation, ureteroscope negotiation, operating time, drug related side effect and procedural
complication were noted in each group.
Results:  All four groups (A, B, C, D) were significantly better than group E in terms of ureteric orifice
appearance (wide) during endoscopy. Negotiation of ureteric orifice was easy in group A (70.59%), B
compare to group E (31.43%) which was statistically significant. Group A
re statistically better with group E (62.86%) in terms of ureteral dilatation.
 four groups as compared to group E. All patients well tolerated the drugs(58.82%) and D (78.13%) as 
(32.35%) and D (34.38%) we
Operative time was less in all
with no serious side effects.Abbreviations: PDE 5i, phospho diesterase 5 inhibitor; UVJ, ureterovesical junction.
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Conclusion:  Both tamsulosin and tamsulosin with tadalafil helps in forward propagation of large size
ureteroscope as compared to other groups with less operative time without any significant complications.
So, we can conclude that tamsulosin alone can be helpful for lower ureteric orifice negotiation during
intracorporeal lithotripsy with minimal side effects.
© 2018 Pan African Urological Surgeons Association. Production and hosting by Elsevier B.V. This is an open























































































arrowest part of human ureter is the ureterovesical junction
UVJ) which provides difficulty in spontaneous stone expulsion
s well as ureteroscope negotiation [1,2]. Peremans described the
icroanatomy of UVJ as three different zones namely the intramural
nd submucosal part of intravesical ureter and the extravesical ureter
t ureteral hiatus [3]. Functionally, three different muscle groups
ith different innervations are present at UVJ namely the detru-
or, inner and outer layer of ureter muscle and muscularis mucosae
4]. After the introduction of first rigid ureteroscope in 1980 by
erez Castro and Martinez Pineiro, several modification and minia-
urization has been occurred for diagnostic and therapeutic accuracy
hat minimizing the morbidity but also compromises the visibility
5–7]. UVJ negotiation is an important part during ureteroscopy and
any patients (almost 40–60%) may require dilatation of ureteric
rifice for negotiation of large size ureteroscope (8/9.8 Fr) [8]. Var-
ous maneuvers have been described for UVJ negotiation (cases in
hich difficulty encountered during traversing the ureteric orifice)
ut none is free from complications [9].
 number of studies had found the role of   blocker and
hosphodiesterase inhibitors (PDE 5i) in ureteric calculus expul-
ion. Although -adrenergic receptors are distributed along the
ntire length of human ureter, highest concentration is present
n the lower ureter. PDE 5i acts on nitric oxide/cyclic guano-
ine monophosphate (cGMP)-signaling pathway that will lead to
ncreased levels of cGMP which is responsible for relaxation of
he smooth muscle of ureter [10,11]. Antagonism of these recep-
ors relaxes the ureteric smooth muscle, reduces ureteral spasm and
romotes expulsion of calculi [12,13]. Ureteric calculus can lead to
nflammatory reaction and mucosal edema and anti-inflammatory
rugs like corticosteroid can reduce the inflammatory response thus
ncreases stone expulsion [2,11,14].
im of our study was to compare the safety and efficacy of   blocker
tamsulosin), PDE 5i (tadalafil), corticosteroid (deflazacort) and
ombination of   blocker with PDE 5i (tamsulosin with tadalafil)
n lower ureteric orifice negotiation by large size ureteroscope prior
o intracorporeal lithotripsy.
ubjects  and  methods
fter taking institutional review board approval (2701/MC/EC/
016), this prospective randomized double blind placebo controlled
tudy was conducted in our department of urology from February
016 to April 2017. Informed written consent was taken from all





ith an uncomplicated, single ureteric stone size 8–15 mm, located
n either lower or mid ureter (up to upper border of sacrum) were
ncluded in this study. Patients either not meeting inclusion criteria
r not willing to participate were excluded from this study (these
atients were 26 in number). Patients who were ready to accept
rugs like alpha blocker (tamsulosin), PDE5i (tadalafil), corticos-
eroids (deflazacort), combination (tamsulosin with tadalafil) and
lacebo (multivitamin) prior to surgery were included in this study.
atients with fever, moderate to gross hydronephrosis, presence
f symptomatic bacteriuria, multiple or bilateral ureteric stones,
tone located at VUJ, patients who passed stone spontaneously,
atients with acute or chronic renal insufficiency, solitary kidney
r congenital urinary abnormality were excluded. Patient having
istory of surgical interventions either open or endoscopic urinary
ract surgery, diabetes, cardiac disease, bleeding diathesis, peptic
lcer or on concomitant treatment with drugs like alpha blocker,
eta-blockers, calcium antagonists or nitrates, immunosuppressant
ithout’s, any malignancy, pregnant or lactating females and patient
ho demand immediate active intervention and not willing to partic-
pate were also excluded from this study. So, finally, 180 patients met
he inclusion criteria and underwent intracorporeal ureteroscopic
ithotripsy.
ll patients satisfying inclusion criteria were randomized into five
roups by use of sequentially numbered, opaque sealed envelopes
SNOSE) method [15]. Group A, B, C, D and E were given, Tam-
ulosin (0.4 mg OD), Tadalafil (5 mg OD), Deflazacort (30 mg OD),
amsulosin (0.4 mg OD) + Tadalafil (5 mg OD) and placebo (multi-
itamin), respectively only for 10 days prior to surgery. All patients
ere informed about the side effects of the drugs. History and physi-
al examination were done in all the patients. General characteristics
f all patients were recorded like age, gender, side, size and location
f calculus, height, weight and BMI. Investigations like serum cre-
tinine, urinalysis with urine culture, ultrasonography, plain X-ray
f the kidneys, ureter, and bladder (KUB) and computed tomogra-
hy (CT) were done in every patient before surgery. The greatest
imension of the stone was taken into consideration as the stone
ize. Postoperatively, X ray KUB and ultrasonography were done
n every patient to know the residual fragment.
ab diclofenac 50 mg was given in each group for pain relief as
nd when required. After 10 days of drug intake, patients of each
roup underwent cystourethroscopy. Ureteric orifice configuration
wide/narrow) was noted and then 0.035 Fr guide wire placed. After
his, 8/9.8 Fr wolf ureteroscope was tried to insert into ureteric orifice
ver guide wire. If ureteroscope was negotiated easily into ureteric
rifice without using any maneuver than procedure was considered
s complete. If ureteroscope could not be negotiated through ureteric
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Assessed for eligibility 
(n=206)
Not mee ng inclusion criteria (n=18)
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Figure  1  Showing 
orifice easily than dilatation was done up to 10 Fr with nottingam
ureteral dilator over guide wire, subsequently ureteroscope passed
and stone removal done. At the end of procedure double J stent was
placed in all patients (as a routine procedure in our institution). Both
cystoscopy and ureteroscopy were done by single senior urologist
only. Ureteric orifice configuration (wide/narrow), negotiation (dif-
ficult and easy), ureteric orifice dilatation required or not, operation
time, procedural complication like mucosal injury/false passage,
hematuria and fever, hospital stay, stone free rate and side effect of
drug were noted in each group.
Statistical analysis was performed with the SPSS, Trial version 23
for Windows statistical software package (SPSS Inc., Chicago, IL,
USA) and Primer. The Categorical data were presented as numbers
(percent) and were compared among groups using Chi square test.
The quantitative data were presented as mean and standard deviation
and were compared using by Students’ t-test, ANOVA Test, post Hoc
Test and Tukey Test to find out the most significant groups among
all the groups. Probability P  value <0.05 was considered statistically
significant.
Results
Fig. 1 shows the study design. Total 180 patient following inclu-
sion criteria were randomly assigned into five groups. There was
a dropout of two patients in group A and two in group B, three in
group C, four in group D and one patient in group E. Reason for this





 design of all groups.
o, 168 patients were left for final analysis out of which 34 patients
ere in group A, 34 in group B, 33 in group C, 32 in group D and
5 in group E.
able 1 shows the pre-procedural characteristics of all the study
articipants. No statistically significant differences were observed
n basic parameters (like patient’s age, gender, side of stone, body
ass index, stone size, and location of stone) in all the groups.
able 2 shows the intra procedural characteristics of all the groups.
reteric orifice was found wide in 25 (73.53%) cases of group A,
3 (67.65%) cases of group B, 15 (45.45%) cases of group C, 25
78.13%) cases of group D and 7 (20%) cases of group E. Nego-
iation of ureteric orifice was easy in 24 (70.59%), 20 (58.82%),
9 (57.58%), 25 (78.13%) and 11 (31.43%) cases of group A, B,
, D and E, respectively whereas ureteral dilatation was required
n 32.35% [11] cases of group A, 41.18% [14] cases of group B,
8.48% [16] cases of group C, 34.38% [11] cases of group D and
2.86% [22] cases of group E. Mean operative time was 34.41,
5.53, 36.12, 33.34 and 45.20 min in group A, B, C, D and E,
espectively.
able 3 shows the statistical analysis of these findings (ureteric ori-
ce appearance, negotiation and requirement of ureteral dilatation)
etween all five groups. With comparative analysis we found that
ll four groups (A, B, C, D) were statistically better than group E in
erms of ureteric orifice appearance (wide) during endoscopy. How-
ver when we compare all these groups with each other, we found
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Table  1  showing the demographic data of all groups.
Parameters Group A Group B Group C Group D Group E P value
Number 34 34 33 32 35
Age (years) (mean ± SD) 35.42 ± 11.4 32.78 ± 14.1 33.32 ± 10.9 36.6 ± 12.8 37.1 ± 10.9 0.488
Sex (Male/Female) 24/10 25/9 24/9 24/8 25/10 0.995
Side (Right/Left) 18/16 19/15 15/18 18/14 16/19 0.822
BMI kg/m2 (mean ± SD) 23.42 ± 3.9 23.98 ± 4.2 22.7 ± 3.6 24.9 ± 4.1 22.9 ± 2.9 0.125
Location of calculus (Middle/Lower) 10/24 9/25 8/25 6/26 10/25 0.869
Size (mm) (mean ± SD) 10.2 ± 2.1 10.7 ± 2.9 12.0 ± 2.5 11.6 ± 2.9 11.3 ± 2.8 0.357











No % No % No % No % No %
Ureteric orifice appearance during endoscopy
Narrow 9 26.47 11 32.35 18 54.55 7 21.88 28 80.00
Wide 25 73.53 23 67.65 15 45.45 25 78.13 7 20.00
Negotiation of ureteric orifice by ureteroscope
Difficult 10 29.41 14 41.18 14 42.42 7 21.88 24 68.57
Easy 24 70.59 20 58.82 19 57.58 25 78.13 11 31.43
Ureteral dilation
Not required 23 67.65 20 58.82 17 51.52 21 65.63 13 37.14
Required 11 32.35 14 41.18 16 48.48 11 34.38 22 62.86
Mean operative time ± (min) 34.41 ± 6.76 35.53 ± 6.99 36.12 ± 7.42 33.34 ± 6.15 45.20 ± .963
Table  3  Showing statistical analysis (P  value) between all groups.
Parameters A vs B A vs c A vs D A vs E B vs c B vs D B vs E C vs D C vs E D vs E
Ureteric orifice appearance during endoscopy
Narrow 0.79 0.036 0.88 0.00 0.39 0.49 0.01 0.014 0.047 <0.001
Wide
Negotiation of ureteric orifice by ureteroscope
Difficult 0.44 0.39 0.67 0.003 0.88 0.15 0.041 0.13 0.054 <0.001
Easy
Ureteral dilation































Mean operative time (min) 0.963 0.848 0.970 0.0
hat ureteric orifice was wide in more cases of group A and D in
ontrast to group C with statistically significant difference. Negoti-
tion of ureteric orifice was easy in group A, B and D as compared
o group E which was statistically significant. Although negotiation
f ureteric orifice was easy in group C as compared to group E,
t was statistically insignificant. Group A and D were statistically
etter with group E in terms of ureteric orifice dilatation; however
roup B and C didn’t show statistical significant difference with
roup E. All four groups (Group A, B, C, D) showed statistically
ignificant difference with group E in terms of operative time. When
e compare all four groups (Group A, B, C, D) with each other, we
idn’t found any statistical significant difference between groups
ith regard to ureteric orifice negotiation, ureteral dilatation and
perative time.
able 4 shows the procedural complications (gross hematuria,





0.997 0.699 0.007 0.484 0.023 0.000
tay of patients in all groups. Table 5 shows statistical analysis
etween all groups regarding these complications. Gross hematuria
as noted in 7, 10, 9, 6 and 17 patients of group A, B, C, D and E,
espectively. Similarly, mucosal injury/false passage was noted in
, 5, 6, 2 and 11 patients of group A, B, C, D and E, respectively
ut statistical significant difference was found only between group
 and D with group E in terms of false passage and gross hema-
uria. Post-operative fever was also noted in some of the patients
f each group but not statistically significant. Stone free rate was
lso not significant between all the groups. Hospital stay was sta-
istically significant between group A, C, and D when compare to
roup E.able 6 shows the drug related side effects. Headache, backache and
yspepsia were higher in patients of Group B and D as compared
o patient of Group A, B and E and was statistically significant (P
alue <0.05). Whereas dizziness and abnormal ejaculation was more
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Table  4  showing post procedural characteristics between all groups.
Parameters Group A (N = 34) Group B (N = 34) Group C (N = 33) Group D (N = 32) Group E (N = 35) P value
Gross hematuria(<24 h/>24 h) 0.16
<24 h 5 8 6 5 15
>24 h 2 2 3 1 2
No 27 24 24 26 18
Mucosal injury/false passage 0.034
Not present 31 29 27 30 23
Present 3 5 6 2 11
Fever 3 2 4 1 8 0.08
Stone free rate 0.75
Free 32 31 30 30 30
Residual 2 3 3 2 5
Hospital stay (in days) 2.12 ± 0.33 2.21 ± 0.41 2.18 ± 0.39 2.13 ± 0.34 2.56 ± 0.93 0.004
Table  5  showing statistical analysis (p value) between all groups regarding post procedural characteristics.
A vs B A vs c A vs D A vs E B vs c B vs D B vs E C vs D C vs E D vs E
Gross hematuria (<24 h/ > 24 h)




Not present 0.7 0.44 0.94 0.03 9.95 0.475 0.15 0.27 0.29 0.019
Present
Fever 1 0.97 0.65 0.65 0.64 0.98 0.09 0.37 0.054 0.057
Stone free rate
Free 1 0.97 0.65 0.44 0.69 0.94 0.74 0.97 0.77 0.5
Residual
Hospital stay (in days) 0.95 0.98 0.99 0 1 0.972 0.053 0.99 0.061 0.01
Table  6  Showing drug related side effects between all groups.
Group A Group B Group C Group D Group E P value
No % No % No % No % No %
Headache, backache 4 11.76 12 35.29 3 9.09 10 31.25 5 14.29 0.017














Abnormal ejaculation 3 8.82 2 5.88 
Dizziness 5 14.71 4 11.76 
common in Group A and D as compared to Group B, C and E which
was statistically insignificant (P  value >0.05).
Discussion
One of the narrowest part of the ureter is the UVJ and urologist
often having difficulty to traverse ureteric orifice by ureteroscope.
For effective ureteroscopy crossing the ureteral orifice is basically a
vital demonstration. Initially ureteroscopy was performed by Young
in 1912 in an infant [16], however it was popularized in 1960s fol-
lowing advances in Dr. Hopkins rod-lens optical systems [17,18].
Miniaturization of ureteroscope may lead to easy negotiation but
with compromised visibility and efficacy for removal of calculi,
on the other hand large size uretroscope require ureteric orifice
dilatation [19,20]. To overcome the difficulty of ureteric orifice





3.03 4 12.50 1 2.86 0.46
12.12 6 18.75 4 11.43 0.902
f either passive dilatation (Double j stent) or active dilatation (bal-
oon, metal, sequential fascial dilators, olives, etc.) but none of these
re free from complications [19–21].
he alpha-1 A and D-adrenergic receptors are most populated adren-
rgic receptors in human ureter. Highest concentration of these 
eceptors are in lower ureter as compared to upper and mid ureter
11,13]. Tamsulosin is most widely studied   blocker for medical
xpulsive therapy and is highly selective 1a blocker so we used
his drug for our study [22]. Gratzke et al. demonstrated the role of
hosphodiesterase inhibitor on ureteric smooth muscle using silde-
afil, vardenafil and tadalafil. As tadalafil is more selective PDE-5
eceptor with less visual side effect [23,24], so we used this drug in
ur study at low dose [23,24]. Larger stones tend to cause inflamma-
ory reactions in ureter and that submucosal edema in the vicinity
















































































orticosteroids stabilize neutrophil lysosomes, therefore decreas-
ng inflammation and edema related to mechanical irritation [25].
eflazacort is a glucocorticoid and it has faster and potent anti-
nflammatory action that can be achieved at a low dose [2]. Medical
xpulsive therapy for distal ureteric stones using combination of
amsulosin plus tadalafil is safe, effective and well tolerated with no
erious adverse events [26].
o the best of our knowledge, this is the first kind of prospective
tudy that assessed use of medications like   blocker and PDE5i
or ease of negotiation of larger size ureteroscope to improve stone
ccess. Ureteric orifice was found narrow and negotiation of orifice
as difficult in group E as compared to other groups. Elashry et al.
sed various size of ureteroscope (6.9 Fr to 11.5 Fr) in manage-
ent of ureteric calculi. In their retrospective study they showed
hat ureteric orifice was dilated in 59.5% of cases, direct intro-
uction of ureteroscope into ureter without dilatation was done in
4.9% of patients either using small size semi rigid ureteroscope
r ureteral stenting preoperatively. Ureteric perforation was noted
n 58 patients, out of which 40 was noted in cases where large
ize ureteroscope used (9 Fr or larger). Similarly out of 18 cases
f ureter avulsion, 17 were noted in cases of large size uretero-
cope [27]. However, we used 8/9.8 Fr wolf ureteroscope, so 62.86%
atients require ureteric orifice dilatation in Group E as compared
o 32.35%, 41.18%, 48.48% and 34.38%patients in Group A, B, C
nd D, respectively.
s shown by Lodh et al. the mean operative time was also higher
roup E as compared to other groups [2]. Reason for this may be the
ifficulty in ureteroscope negotiation and need for ureteral dilata-
ion. In our study, high incidence (32.35%) of mucosal injury/false
assage was noted in the group E as compared to other groups. This
ay be due to tight ureteric orifice and need for frequent dilation of
reteric orifice while entering through the inflamed ureteric orifice
28]. In their study of iatrogenic ureteric injury following URSL, Al-
wadi et al. found it as by considered it as one of the most common
omplications [29]. Some investigator reported higher incidence of
omplications like mucosal injury, hematuria and ureteral avulsion
n patients who were treated with large size ureteroscope [30]. We
lso noted similar findings in group E as compared to other groups.
lthough some of our patients also noted complications during drug
ntake, these were not much severe and all patients tolerated drug.
ain limitation of our study was the small sample size, single cen-
er study, short follow up and subjective intraoperative findings like
reteric orifice appearance (narrow/wide) and orifice negotiation.
lthough the complications rate and need for dilatation was high
nd easy negotiation rate was low in our study as compared to some
revious studies, we think that main reason of this was due to choos-
ng a low threshold for reporting these complications as most of these
omplications were subjective in nature.
onclusion
e found that both tamsulosin and tamsulosin with tadalafil not only
elax ureteral smooth muscle but also helps in forward propagation
f large size ureteroscope as compared to deflazacort, tadalafil or
lacebo without any significant complications with less operative
ime. However, drug related side effect like headache and backache
ere more significant in combination group as compared to tam-
ulosin alone. So, we can conclude that tamsulosin alone can be
[
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ithotripsy with minimal side effects.
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